In terms of partnership Wayne, the Sarepta / Roche deal is the closest we have to compare that is in our space - although i notice PER have taken that refence out of the company presentation.
Roche paid $1B up front to Sarepta for global rights outside of USA market (Gene Therapy).
Maybe GT carries a premium ...but so does inflammation control, which will allow Sarepta's and Pfizer's GT drugs to produce more dystrophin.
A partnership for US market, and PER keeping rest of world may be a good outcome.
It's reassuring to hear the CEO confirm that boys who have completed the first 6 months of trial, continuing on the program with either 25mg or 50mg dose.
.
.
In terms of partnership Wayne, the Sarepta / Roche deal is the...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |